Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 3.19% is 56% below its 5-year average of 7.22%, near the high end of its 5-year range (-231.96%–28.09%).
11.55% below its 12-month average of 3.61%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -14.84%.
NET PROFIT MARGIN
3.19%
NET PROFIT MARGIN AVG TTM
3.61%
NET PROFIT MARGIN AVG 3Y
5.69%
NET PROFIT MARGIN AVG 5Y
7.22%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-11.55%
CURRENT VS 3Y AVG
-43.96%
CURRENT VS 5Y AVG
-55.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Market Cap
$52.46M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$52.65M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$51.34M
Net Profit Margin
-11304.83%
TTM Avg
-9549.74%
3Y Avg
-8821.76%
5Y Avg
-6347.57%
Market Cap
$51.28M
Net Profit Margin
-618.02%
TTM Avg
-2368.57%
3Y Avg
-1184.28%
5Y Avg
-1443.19%
Market Cap
$51.13M
Net Profit Margin
N/A
TTM Avg
-24.71%
3Y Avg
-12.36%
5Y Avg
-8.24%
Market Cap
$51.05M
Net Profit Margin
-20059.90%
TTM Avg
-12303.49%
3Y Avg
-9625.39%
5Y Avg
-8201.08%
Market Cap
$50.64M
Net Profit Margin
-91866.00%
TTM Avg
-196225.86%
3Y Avg
-104777.73%
5Y Avg
-90977.38%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| biote Corp. (BTMD) | $51.61M | 3.19% | 3.61% | 5.69% | 7.22% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.65M | 0.00% | 0.00% | 0.00% | 0.00% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Envoy Medical, Inc. (COCH)vs › | $51.34M | -11304.83% | -9549.74% | -8821.76% | -6347.57% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.28M | -618.02% | -2368.57% | -1184.28% | -1443.19% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.13M | N/A | -24.71% | -12.36% | -8.24% |
| Clene Inc. (CLNN)vs › | $51.05M | -20059.90% | -12303.49% | -9625.39% | -8201.08% |
| INmune Bio, Inc. (INMB)vs › | $50.64M | -91866.00% | -196225.86% | -104777.73% | -90977.38% |
| Celularity Inc. (CELU)vs › | $50.58M | -375.77% | -226.26% | -308.90% | -527.22% |
Operating Margin
18.5%
Net Profit Margin
3.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -14.84% |
| 2026-03-31 | 5.07% |
| 2025-12-31 | 4.21% |
| 2025-09-30 | 17.07% |
| 2025-06-30 | 6.52% |
| 2025-03-31 | 28.00% |
| 2024-12-31 | 7.43% |
| 2024-09-30 | 20.83% |
| 2024-06-30 | -14.41% |
| 2024-03-31 | -8.89% |
| 2023-12-31 | 16.92% |
| 2023-09-30 | 16.53% |
| 2023-06-30 | -10.44% |
| 2023-03-31 | -15.18% |
| 2022-12-31 | -231.96% |
| 2022-09-30 | 0.04% |
| 2022-06-30 | -6.30% |
| 2022-03-31 | 25.17% |
| 2021-12-31 | 14.60% |
| 2021-09-30 | 24.00% |
| 2021-06-30 | 28.09% |
| 2021-03-31 | 28.03% |
| 2020-12-31 | 30.66% |
